Company news: Corcept Therapeutics and Daiichi Sankyo

Share this article:

Corcept Therapeutics said Thursday its Cushing's syndrome drug will be launched April 11, three weeks earlier than expected. Korlym (mifepristone) will wholesale at $0.62 per milligram, or $186 per 300-mg tablet, VP of commercial operations Steven Lo told MM&M. The FDA approved the once-a-day treatment in February. It's the first FDA-sanctioned drug for the rare disease. Lo said the company had set an internal goal to have Korlym hit pharmacy shelves soon after April 8, which is Cushing's Awareness Day.

Daiichi Sankyo is starting April with a new global slogan: "Passion for Innovation. Compassion for Patients." It will be the first uniform slogan for the company since the 2006 merger which brought Daiichi Pharmaceutical and Sankyo under one roof. Marah Binder, DSI senior manager for corporate public relations, told MM&M that the slogan is part of a push toward a unified global image, and that the company had been sifting through iterations for more than a year. The new tagline will be slowly rolled out as of the first of the month.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters